000			04115nam a22003375i 4500
999			_c402728 _d402728
001			402728
003			ES-MaUEC
005			20240615164251.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			231014s2023 sz | fo |||| 0|eng d
020			_a9783031292231
024	7		_a10.1007/978-3-031-29223-1 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280 _b2023 EB
245	0	0	_aImmunotherapy for Head and Neck Cancer _cedited by Anthony T C Chan, Brigette BY Ma
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCancer Immunotherapy _x2662-8392 ; _v1
505	0		_aImmunological Landscape of Head and Neck Cancer: Mechanisms of Immune Escape and the Tumor Microenvironment -- Drug Targets and Strategies in the Clinical Development of Immunotherapy for Head and Neck Cancer -- Immunotherapy in Locally Advanced Nasopharyngeal Carcinoma -- Immunotherapy in Recurrent and Metastatic Nasopharyngeal Carcinoma -- Beyond PD-1/PD-L1 Immune Checkpoint Inhibitors: Other Targets and Approaches for Head and Neck Cancer -- Translational and Clinical Approach to Combining Immunotherapy with Radiotherapy in the Treatment of Head and Neck Cancer -- Clinical Application of Immunotherapy in the Perioperative Management of Head and Neck Cancer -- The Role of Immune Checkpoint Inhibitors in the Treatment of Less Common Head and Neck Cancers -- Development of Predictive Biomarkers to Immunotherapy in Head and Neck Cancer. .
520			_aThis book is a comprehensive summary of the literature on the scientific rationale and clinical development of immunotherapy for head and neck cancers. Head and neck cancer is a biologically diverse group of cancers that bear a common hallmark - evasion of host immune surveillance through innate or acquired mechanisms. The etiological association between the Human Papilloma virus (HPV) and some squamous head and neck cancers, the Epstein-Barr virus (EBV) and nasopharyngeal cancer has provided further impetus for evaluating immunotherapy in this group of cancers. The successful development of anti-programmed cell death protein-1 (PD-1)/ ligand (PD-L1) and CTLA-4 antibodies in solid tumours has gradually brought immunotherapy into mainstream oncological practice in recent years. Besides immune-checkpoint proteins inhibitors, other forms of immunotherapy such as vaccines, EBV or HPV-targeting therapies and cellular therapies are actively being investigated in clinical trials, either alone or in combination with other conventional treatments such as radiotherapy, chemotherapy and surgery. In clinical setting, the practicing oncologist need to be familiar with some unusual patterns of immunological response such as pseudo-progression and hyper-progression in patients with head and neck cancers who are undergoing treatment with immune-checkpoint inhibitors. Furthermore, the unique side effects of immune-checkpoint inhibitors such as autoimmune toxicities need to be recognized early and treated expediently. The development of biomarkers in predicting response to immune-checkpoint inhibitors has played pivotal roles in selecting patients for immunotherapy in practice or as an enrichment strategy in clinical trials. There are now emerging data on the clinical utility of biomarkers such as PD-L1 expression (Combined Positive Score), gene signatures and tumor mutational burden. This book is an invaluable companion to all those who are involved in research and clinical management of patients with head and neck cancers from any endemic regions. .
988			_aSpringer_Medicine_2023
650		7	_2embne _9210886 _aCabeza _xCáncer _xInmunoterapia
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-29223-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b06/2024 _dz _ean _zSI